Replies to At this point, ALTA3263 is still in Phase 1 testing, so there is very limited human...

Discussion

Pancreatic Cancer | Last Active: 5 days ago | Replies (2)

Comment receiving replies

@mcharlesfrancis

At this point, ALTA3263 is still in Phase 1 testing, so there is very limited human side-effect data publicly available. The trial's primary purpose is to determine safety, tolerability, and dosing.

Based on experience with other KRAS inhibitors, oncologists will likely be watching closely for:

Diarrhea
Nausea
Fatigue
Rash or skin changes
Elevated liver enzymes
Decreased appetite
Blood count abnormalities

Jump to this post

Replies to "At this point, ALTA3263 is still in Phase 1 testing, so there is very limited human..."

howleegirl | @howleegirl | 5 days ago

@mcharlesfrancis I believe it is in late stage 1 testing. They started my husband on 300mg 2x a day. He's only been on it 5 days and has started to get occasional diarrhea, nausea, and fatigue. All seem to be controllable.

VIEW AND REPLY